Mga Batayang Estadistika
| CIK | 1829280 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Forian Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 25, 2025 |
Forian Receives Unsolicited Proposal from CEO to be Taken Private Exhibit 99.1 Forian Receives Unsolicited Proposal from CEO to be Taken Private NEWTOWN, PA, August 25, 2025 – Forian Inc. (NASDAQ:FORA) (“Forian” or the “Company”), a leading provider of data science driven information and analytics solutions to the life science, healthcare and financial services industries, announced today that its Board of Directors has received an unsolicited, preliminary, non- |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2025 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2025 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| August 15, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-8 (Form Type) FORIAN INC. (Exact Name of Registrant as Specified in its Charter) Table 1-Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per s |
|
| August 15, 2025 |
As filed with the Securities and Exchange Commission on August 15, 2025 As filed with the Securities and Exchange Commission on August 15, 2025 Registration No. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its charte |
|
| August 13, 2025 |
Forian Inc. Announces Second Quarter 2025 Financial Results Exhibit 99.1 Forian Inc. Announces Second Quarter 2025 Financial Results Newtown, PA, August 13, 2025 (GLOBE NEWSWIRE) – Forian Inc. (Nasdaq: FORA), a leading provider of data science driven information and analytics solutions to the life science, healthcare and financial services industries, today announced results for the quarter ended June 30, 2025. “Our strong second quarter results reflect co |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 26, 2025 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| July 1, 2025 |
Exhibit 16.1 CBIZ CPAs P.C. One Montgomery Street Suite 1700 San Francisco, CA 94104 P: 415.432.6200 July 1, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Forian Inc. under Item 4.01 of its Form 8-K dated June 26, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2025 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| June 16, 2025 |
FORIAN INC. SECOND AMENDMENT TO 2020 EQUITY INCENTIVE PLAN Exhibit 10.1 FORIAN INC. SECOND AMENDMENT TO 2020 EQUITY INCENTIVE PLAN This Second Amendment (the “Amendment”) to the 2020 Equity Incentive Plan (the “Plan”) of Forian Inc., a Delaware corporation (the “Company”), is effective as of the date set forth below. Capitalized terms used and not defined herein shall have the meanings given to such terms in the Plan. Background A. The Plan was establishe |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its chart |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2025 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 14, 2025 |
Forian Inc. Announces First Quarter 2025 Financial Results Exhibit 99.1 Forian Inc. Announces First Quarter 2025 Financial Results Newtown, PA, May 14, 2025 (GLOBE NEWSWIRE) – Forian Inc. (Nasdaq: FORA), a leading provider of data science driven information and analytics solutions to the life science, healthcare and financial services industries, today announced results for the quarter ended March 31, 2025. “We delivered first quarter results that continu |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2025 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| April 29, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 28, 2025 |
Exhibit 16.1 April 28, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Forian Inc. under Item 4.01 of its Form 8-K dated April 24, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Forian Inc. contained therein. Very truly |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 24, 2025 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| April 11, 2025 |
Exhibit 21 SUBSIDIARIES Subsidiary Jurisdiction Helix Technologies, Inc. Delaware Forian LLC (f/k/a Medical Outcomes Research Analytics, LLC) Delaware Helix Legacy, Inc. Delaware Green Tree International, Inc. Colorado Kyber Data Science LLC Delaware Kyber Aesthetic Data LLC Kyber Data Sub LLC Kyber Health Data LLC Kyber Survey Data LLC Delaware Delaware Delaware Delaware |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its c |
|
| April 1, 2025 |
SEC FILE NUMBER: 001-40146 CUSIP NUMBER: 34630N106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in the form shall be construed to imply that the Commission has verified any information contained herein. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| January 27, 2025 |
EX-1 2 ef20042359ex1.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the common stock, $0.001 par value per share, of Forian Inc., and further agree that t |
|
| January 16, 2025 |
The accompanying notes are an integral part of these consolidated financial statements. Exhibit 99.2 Kyber Data Science LLC Consolidated Financial Statements (unaudited) September 30, 2024 Kyber Data Science LLC Contents As of September 30, 2024 Page(s) Consolidated Financial Statements Consolidated Balance Sheet (unaudited) 1 Consolidated Statement of Operations (unaudited) 2 Consolidated Statement of Changes in Members’ Equity (unaudited) 3 Consolidated Statement of Cash Flows (una |
|
| January 16, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2024 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commi |
|
| January 16, 2025 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Unless the context otherwise requires, the “Company” refers to Forian Inc., a Delaware corporation, and “Kyber” refers to Kyber Data Science LLC, a Delaware limited liability company. Description of the Business Combination On October 31, 2024, Forian Inc. (the “Company”) entered into a Membership Interest Assignment Agreeme |
|
| January 16, 2025 |
Report of Independent Auditors Exhibit 99.1 Kyber Data Science LLC Consolidated Financial Statements December 31, 2023 Kyber Data Science LLC Contents As of December 31, 2023 Page(s) Report of Independent Auditors 1-2 Consolidated Financial Statements Consolidated Balance Sheet 3 Consolidated Statement of Operations 4 Consolidated Statement of Changes in Members' Equity 5 Consolidated Statement of Cash Flows 6 Notes to Consolid |
|
| November 13, 2024 |
CONVERTIBLE PROMISSORY NOTE REDEMPTION AGREEMENT Exhibit 10.1 CONVERTIBLE PROMISSORY NOTE REDEMPTION AGREEMENT This CONVERTIBLE PROMISSORY NOTE REDEMPTION AGREEMENT (this “Agreement”) is made and entered into effective as of November 12, 2024 (the “Effective Date”), among Forian Inc., a Delaware corporation (the “Company”), on the one hand, and each holder set forth on the signature page hereto (each individually a “Seller” and collectively the |
|
| November 13, 2024 |
Forian Inc. Announces Third Quarter 2024 Financial Results Exhibit 99.1 Forian Inc. Announces Third Quarter 2024 Financial Results Newtown, PA, November 13, 2024 (GLOBE NEWSWIRE) – Forian Inc. (Nasdaq: FORA), a leading provider of data science driven information and analytics solutions to the life science, healthcare and financial services industries, today announced results for the quarter ended September 30, 2024. “While this quarter’s revenue remained |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its c |
|
| November 6, 2024 |
Forian Acquires Kyber Data Science to Enhance Data Analytics Capabilities Exhibit 99.1 Forian Acquires Kyber Data Science to Enhance Data Analytics Capabilities Newtown, PA, November 1, 2024 (GLOBE NEWSWIRE) – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced it has acquired Kyber Data Science LLC (“Kyber”), a trusted provider of advanced healthcare data analy |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2024 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| November 6, 2024 |
Exhibit 2.1 Execution Version Confidential MEMBERSHIP INTEREST ASSIGNMENT AGREEMENT by and among Cowen Inc., IMcK Holdings LLC, Kyber Data Science LLC, and Forian Inc. Dated as of October 31, 2024 THIS DOCUMENT SHALL BE KEPT CONFIDENTIAL PURSUANT TO THE TERMS OF THE NONDISCLOSURE AGREEMENT ENTERED INTO BETWEEN FORIAN INC. AND THE TORONTO-DOMINION BANK, DATED AS OF OCTOBER 30, 2023. TABLE OF CONTEN |
|
| August 14, 2024 |
Forian Inc. Announces Second Quarter 2024 Financial Results Exhibit 99.1 Forian Inc. Announces Second Quarter 2024 Financial Results Newtown, PA, August 14, 2024 (GLOBE NEWSWIRE) – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter ended June 30, 2024. “We continued to invest in our information assets in the second quarter |
|
| August 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2024 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its charte |
|
| June 14, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2024 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 14, 2024 |
Forian Inc. Announces First Quarter 2024 Financial Results Exhibit 99.1 Forian Inc. Announces First Quarter 2024 Financial Results Newtown, PA, May 14, 2024 (GLOBE NEWSWIRE) – via NewMediaWire – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter ended March 31, 2024. “We navigated through the expected tough first quarter e |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its chart |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2024 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| April 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| March 29, 2024 |
FORIAN INC. INCENTIVE COMPENSATION RECOUPMENT POLICY Exhibit 97 FORIAN INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1. Introduction. The Board of Directors (the “Board”) of Forian Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has th |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its c |
|
| March 29, 2024 |
Exhibit 19 Insider Trading Policy I. Introduction During the course of your service with Forian Inc. or any subsidiary of Forian Inc. (collectively, the “Company”) as (i) a member of our Board of Directors; (ii) an employee or (iii) an advisor or consultant, you may receive important information that is not yet publicly available (“inside information”) about the Company or about other publicly tra |
|
| March 29, 2024 |
Exhibit 21 SUBSIDIARIES Subsidiary Jurisdiction Helix Technologies, Inc. Delaware Medical Outcomes Research Analytics, LLC Delaware Helix Legacy, Inc. Delaware Green Tree International, Inc. Colorado |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2024 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| March 28, 2024 |
Exhibit 99.1 Forian Inc. Announces Fourth Quarter and Full Year 2023 Financial Results Full year 2023 revenue grew 25% Full year 2023 Adjusted EBITDA of $2.3MM Newtown, PA, March 28, 2024 (GLOBE NEWSWIRE) – via NewMediaWire – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for |
|
| February 13, 2024 |
FORA / Forian Inc. / FEINBERG LARRY N - SC 13G/A Passive Investment SC 13G/A 1 tm245975d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 FORIAN INC. (Name of Issuer) Common Stock (Title of Class of Securities) 34630N106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| December 22, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2023 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| December 22, 2023 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. AMENDMENT 2 This SECOND Amendment (this “Amendment 2”) is entered into effective as of December 20, 2023 (the “Amendment 2 Effective Date”), by and between |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its c |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2023 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| November 9, 2023 |
Exhibit 99.1 Forian Inc. Announces Third Quarter 2023 Financial Results Third quarter revenue grew 24% year-over-year Forian data factory expanded to drive improved insights Newtown, PA, November 9, 2023 (GLOBE NEWSWIRE) – via NewMediaWire – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announ |
|
| October 4, 2023 |
Forian Inc. Announces Stock Repurchase Exhibit 99.1 Forian Inc. Announces Stock Repurchase Newtown, PA, October 3, 2023 (GLOBE NEWSWIRE) – via NewMediaWire – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced that it has repurchased an aggregate of 1,604,676 shares of Forian common stock in a privately negotiated transaction a |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 3, 2023 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its charte |
|
| August 10, 2023 |
Exhibit 99.1 Forian Inc. Announces Second Quarter 2023 Financial Results Second quarter revenue grew 36% year-over-year Newtown, PA, August 10, 2023 (GLOBE NEWSWIRE) – via NewMediaWire – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter ended June 30, 2023. “Foria |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| July 27, 2023 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 21, 2023 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| June 15, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2023 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its chart |
|
| May 12, 2023 |
Exhibit 99.1 Forian Inc. Announces First Quarter 2023 Financial Results First quarter revenue grew 38% year over year Newtown, PA, May 12, 2023 (GLOBE NEWSWIRE) – via NewMediaWire – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter ended March 31, 2023. “As we con |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2023 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 30, 2023 |
Exhibit 21 SUBSIDIARIES Subsidiary Jurisdiction Helix Technologies, Inc. Delaware Medical Outcomes Research Analytics, LLC Delaware Helix Legacy, Inc. Delaware Green Tree International, Inc. Colorado |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its c |
|
| March 27, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2023 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| March 27, 2023 |
Forian Inc. Announces Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Forian Inc. Announces Fourth Quarter and Full Year 2022 Financial Results Fourth quarter revenue grew 37% year-over-year Forian exits cannabis industry with sale of BioTrack for $30 million Newtown, PA, March 27, 2023 (GLOBE NEWSWIRE) - via NewMediaWire - Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life scienc |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2023 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 13, 2023 |
[Signatures on Following Page] Exhibit 10.2 Forian Inc. 41University Drive Suite 400 Newtown, PA 18940 February 10, 2023 Via Email Daniel Barton [*****] [*****] Re: Separation and Release Agreement Dear Dan: With our sincere thanks for your service to Forian Inc. (together with its subsidiary and affiliated companies, collectively the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of our |
|
| February 13, 2023 |
Exhibit 2.1 STOCK PURCHASE AGREEMENT BY AND AMONG BIO-TECH MEDICAL SOFTWARE, INC., HELIX TECHNOLOGIES, INC. AND BT ASSETS GROUP, INC. DATED AS OF FEBRUARY 10, 2023 TABLE OF CONTENTS Page SECTION 1 DEFINITIONS 1 1.1 Definitions 1 SECTION 2 THE TRANSACTIONS 12 2.1 Purchase and Sale of Company Common Stock 12 2.2 Time and Place of Closing 12 2.3 Closing Payments 12 2.4 Subsequent Cash Payments 12 2.5 |
|
| February 13, 2023 |
Exhibit 10.1 LICENSE AGREEMENT THIS LICENSE AGREEMENT (this “Agreement”), dated as of February 10, 2023 (the “Effective Date”), is made and entered into by and among Forian Inc., a Delaware corporation (“Forian”) and Helix Technologies, Inc., a Delaware Corporation (“Seller” and together with Forian, the “Licensees”), each for itself and for the benefit of their respective Affiliates, collectively |
|
| February 13, 2023 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Sale of BioTrack On February 10, 2023, Helix Technologies, Inc., a Delaware corporation (“Helix”) and a wholly owned subsidiary of Forian Inc. (the “Company”), completed the sale of 100% of the outstanding capital stock of its wholly owned subsidiary, Bio-Tech Medical Software, Inc., a Florida corporation (“BioTrack”), t |
|
| February 13, 2023 |
Forian Announces the Sale of BioTrack to Alleaves Exhibit 99.1 Forian Announces the Sale of BioTrack to Alleaves Newtown, PA and Deerfield Beach, FL, February 13, 2023 (GLOBAL NEWSWIRE) - Forian Inc. (Nasdaq: FORA), a provider of technology, analytics and data science driven solutions, today announced the sale of Forian’s cannabis software subsidiary, Bio-Tech Medical Software, Inc. (d/b/a BioTrack), to Alleaves, Inc., a provider of ERP software |
|
| February 9, 2023 |
FORA / Forian Inc. / FEINBERG LARRY N - SC 13G/A Passive Investment SC 13G/A 1 tm236170d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1* Under the Securities Exchange Act of 1934 FORIAN INC. (Name of Issuer) Common Stock (Title of Class of Securities) 34630N106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| November 18, 2022 |
FORIAN INC. 2020 EQUITY INCENTIVE PLAN Exhibit 4.3 FORIAN INC. 2020 EQUITY INCENTIVE PLAN The purpose of the Forian Inc. 2020 Equity Incentive Plan is to provide (i) designated employees of Forian Inc. (the ?Company?) and its parents and subsidiaries, (ii) certain consultants and advisors who perform services for the Company or its parents or subsidiaries and (iii) non-employee members of the Board of Directors of the Company (the ?Boa |
|
| November 18, 2022 |
As filed with the Securities and Exchange Commission on November 18, 2022 As filed with the Securities and Exchange Commission on November 18, 2022 Registration No. |
|
| November 18, 2022 |
EX-FILING FEES 5 brhc10044309ex107.htm EXHIBIT 107 Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-8 (Form Type) FORIAN INC. (Exact Name of Registrant as Specified in its Charter) Table 1-Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registrat |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its c |
|
| November 14, 2022 |
Forian Inc. Announces Third Quarter 2022 Financial Results Exhibit 99.1 Forian Inc. Announces Third Quarter 2022 Financial Results Revenue grows to $7.2 million On track to exceed 2022 revenue guidance Newtown, PA / November 14, 2022 / Forian Inc. (Nasdaq: FORA), a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, today announced results for the quarter ended September 30, 2022. ?Forian?s third |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2022 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its charte |
|
| August 11, 2022 |
Forian Inc. Announces Second Quarter 2022 Financial Results Exhibit 99.1 Forian Inc. Announces Second Quarter 2022 Financial Results Revenue grows to $6.5 million Reaffirms 2022 revenue guidance of $25.5 to $27.0 million Newtown, PA / August 11, 2022 / Forian Inc. (Nasdaq: FORA), a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, today announced results for the quarter ended June 30, 2022. ?For |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2022 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| August 3, 2022 |
Forian Inc. 41 University Drive Suite 400 Newtown, PA 18940 August 3, 2022 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Forian Inc. Form 10-K for the Year Ended December 31, 2021, as filed March 31, 2022 Form 10-Q for the Quarter Ended March 31, 2022, as filed May 13, 2022 File No. 001-40146 This letter is in response to |
|
| June 21, 2022 |
FORIAN INC. FIRST AMENDMENT TO 2020 EQUITY INCENTIVE PLAN Exhibit 10.1 FORIAN INC. ? FIRST AMENDMENT TO 2020 EQUITY INCENTIVE PLAN This First Amendment (the ?Amendment?) to the 2020 Equity Incentive Plan (the ?Plan?) of Forian Inc., a Delaware corporation (the ?Company?), is effective as of the date set forth below. Capitalized terms used and not defined herein shall have the meanings given to such terms in the Plan. Background A.?The Plan was establishe |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2022 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its chart |
|
| May 12, 2022 |
Forian Inc. Announces First Quarter 2022 Financial Results Exhibit 99.1 Forian Inc. Announces First Quarter 2022 Financial Results Revenue grows to $6.4 million Reaffirms 2022 revenue guidance of $25.5 to $27.0 million Newtown, PA / May 12, 2022 / Forian Inc. (Nasdaq: FORA), a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, today announced results for the quarter ended March 31, 2022. ?The fi |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2022 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| April 28, 2022 |
DEF 14A 1 ny20003470x2def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Prelimin |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| April 14, 2022 |
FORA / Forian Inc. / FEINBERG LARRY N - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 FORIAN INC. (Name of Issuer) Common Stock (Title of Class of Securities) 34630N106 (CUSIP Number) April 4, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? Rule 13d-1(b) |
|
| April 14, 2022 |
SCHEDULE 13G JOINT FILING AGREEMENT Exhibit 99.1 SCHEDULE 13G JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (as so amended, the ?Schedule 13G?) with respect to the common stock of Forian Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Ac |
|
| April 8, 2022 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 8, 2022 Forian Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| March 31, 2022 |
Exhibit 21 SUBSIDIARIES Helix Technologies, Inc. Medical Outcomes Research Analytics, LLC Helix TCS, LLC Security Consultants Group, LLC Helix Legacy, Inc. Bio-Tech Medical Software, Inc. Green Tree International, Inc. Engeni, LLC Engeni, S.A. |
|
| March 31, 2022 |
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock, certain provisions of our Certificate of Incorporation (the ?Certificate of Incorporation?), our Bylaws (?Bylaws?), and certain provisions of Delaware law are summaries. The following is qualified in its entirety by our Certificate of Incorporation and our Bylaws, each of which is filed as an exhibit to our An |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its c |
|
| March 24, 2022 |
Exhibit 99.1 Forian Inc. Announces Fourth Quarter and Full Year 2021 Financial Results FY21 revenue of $16.9 million met high end of revenue outlook Company provides outlook for continued growth in FY22 Newtown, PA / March 24, 2022 / Forian Inc. (NASDAQ: FORA), a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, today announced results |
|
| March 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 24, 2022 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| March 15, 2022 |
Exhibit 99.1 Roth ConferenceMarch 2022 Corporate Overview Safe Harbor This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and fin |
|
| March 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2022 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| February 14, 2022 |
FORA / Forian Inc. / Max Wygod Family Dynasty Trust - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 FORIAN INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34630N 106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 14, 2022 |
FORA / Forian Inc. / Dublin Adam H - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 FORIAN INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34630N 106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 14, 2022 |
FORA / Forian Inc. / Spaniel Edward Francis Jr - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 FORIAN INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34630N 106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 14, 2022 |
FORA / Forian Inc. / Coleman Thomas Jason - SCHED 13G Passive Investment SC 13G 1 s13gforian-090121.htm SCHED 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) * Forian Inc. (Name of Issuer) Common Stock, $.001 par value ( |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2021 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended SEPTEMBER 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its c |
|
| November 15, 2021 |
Exhibit 10.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this ?Agreement?), dated as of September 1, 2021, is made by and among Forian Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a ?Purchaser? and collectively, the ?Purchasers?). BACKGROUND A. The Company and the Purchaser |
|
| November 12, 2021 |
Exhibit 99.1 Forian Inc. Announces Third Quarter Fiscal 2021 Financial Results Third Quarter Revenue of $5.0 Million, Up $4.8 Million Year-Over-Year, Pro Forma Year-Over-Year Growth of 62% Newtown, PA / November 11, 2021 / Forian Inc. (NASDAQ: FORA), a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, today announced results for the fis |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 11, 2021 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| September 13, 2021 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the common stock, $0. |
|
| September 13, 2021 |
FORA / Forian Inc. / WYGOD MARTIN J - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* FORIAN INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 34630N 106 (CUSIP Number) Martin J. Wygod P.O. Box 7188 Rancho Santa Fe, CA 92067 (201) 703-3419 (Name, Address and Telephone Number of Person Authorized |
|
| September 2, 2021 |
Exhibit 99.1 Forian Inc. Announces $24 Million Private Placement of 3.5% Convertible Notes due 2025, Appoints New Chief Financial Officer Newtown, PA / September 1, 2021 / Forian Inc. (NASDAQ: FORA), a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, today announced the following: Convertible Notes Offering The Company has entered into |
|
| September 2, 2021 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of September 2, 2021, by and between Forian Inc., a Delaware corporation (the ?Company?), and Michael Vesey (?Executive?). The Company and Executive desire to enter into this Agreement to establish and govern the terms and conditions of Executive?s employment by the Company or any parent or subsidiary as may |
|
| September 2, 2021 |
Exhibit 10.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this ?Agreement?), dated as of September 1, 2021, is made by and among Forian Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a ?Purchaser? and collectively, the ?Purchasers?). BACKGROUND A. The Company and the Purchaser |
|
| September 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 1, 2021 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| September 2, 2021 |
Exhibit 10.3 Forian Inc. 41 University Drive Suite 400 Newtown, PA 18940 September 2, 2021 Via Email Cliff Farren #### #### #### Re: Transition and Release Agreement Dear Cliff: With our sincere thanks for your service, this letter (this ?Agreement?) sets forth the terms of our mutual agreement regarding your transition and departure from the employ of Forian Inc. (including its subsidiaries, the |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its charte |
|
| August 12, 2021 |
Exhibit 99.1 Forian Inc. Announces Second Quarter Fiscal 2021 Financial Results Second Quarter Revenue of $4.5 Million, Up $4.4M Year-Over-Year, Pro Forma Year-Over-Year Growth of 54% Newtown, PA / August 12, 2021 / Forian Inc. (NASDAQ: FORA), a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, today announced results for the fiscal qua |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2021 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 17, 2021 |
Exhibit 99.1 Forian Inc. Announces First Quarter Fiscal 2021 Financial Results Completes Helix Combination First Quarter Pro Forma Revenue of $3.8 Million, up 22% year-over-year Newtown, PA / May 17, 2021 / Forian Inc. (NASDAQ: FORA), a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, today announced results for its fiscal first quarte |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its chart |
|
| May 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2021 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer I |
|
| April 13, 2021 |
Forian Inc. Announces $12 Million Private Placement of Common Stock Exhibit 99.1 Forian Inc. Announces $12 Million Private Placement of Common Stock Newtown, PA / April 12, 2021 / Forian Inc. (Nasdaq:FORA), a provider of software and technology-enabled services for the healthcare and cannabis industries, announced today that it has entered into a securities purchase agreement with a select group of institutional and accredited investors to raise gross proceeds of |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2021 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer |
|
| April 13, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of April 12, 2021, is made by and among Forian Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a ?Purchaser? and collectively, the ?Purchasers?). BACKGROUND A. The Company and the |
|
| April 6, 2021 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 6, 2021 (March 2, 2021) FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission |
|
| April 6, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The unaudited pro forma condensed combined financial information is presented to illustrate the estimated effects of the merger among Forian Inc. (?Forian? or the ?Company?), DNA Merger Sub, Inc. (?Merger Sub?) and Helix Technologies, Inc. (?Helix?) and the contribution between Forian and Medical Outcomes Research Analytics, |
|
| April 6, 2021 |
Exhibit 99.1 HELIX TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS December 31, 2020 and 2019 HELIX TECHNOLOGIES, INC. AND SUBSIDIARIES PAGE Reports of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets as of December 31, 2020 and 2019 F-5 Consolidated Statement of Operations for the years ended December 31, 2020 and 2019 F-6 Consolidated Statements |
|
| March 31, 2021 |
MEDICAL OUTCOMES RESEARCH ANALYTICS, LLC Exhibit 10.3 MEDICAL OUTCOMES RESEARCH ANALYTICS, LLC Confidential March 25, 2020 Max Wygod Re: Conditional Offer of Employment Hi Max, This offer letter provides the key details of our conditional offer of employment to you by Medical Outcomes Research Analytics, LLC (?MOR?) with respect to the business of MOR and its subsidiaries (together with MOR, the ?Company Group?). Position You will serve |
|
| March 31, 2021 |
Exhibit 10.5 Execution Copy EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of October 16, 2019 (the ?Effective Date?), by and between Medical Outcomes Research Analytics, LLC, a Delaware limited liability company (the ?Company?), and Daniel Barton (?Executive?). The Company and Executive desire to enter into this Agreement to establish and govern the terms and conditi |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-40146 FORIAN INC. (Exact name of registrant as specified in its c |
|
| March 31, 2021 |
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock, certain provisions of our Certificate of Incorporation (the ?Certificate of Incorporation?), our Bylaws (?Bylaws?), and certain provisions of Delaware law are summaries. The following is qualified in its entirety by our Certificate of Incorporation and our Bylaws, each of which is filed as an exhibit to our An |
|
| March 31, 2021 |
FORIAN INC. SPECIAL ADVISOR AGREEMENT Exhibit 10.7 EXECUTION COPY FORIAN INC. SPECIAL ADVISOR AGREEMENT THIS SPECIAL ADVISOR AGREEMENT (?Agreement?) is made and entered into as of January 26, 2021 by and between Forian Inc. (the ?Company?) and Scott Ogur (?Advisor?) (the Company and Advisor collectively referred to as the ?Parties?, and the Company, together with each such subsidiary and/or parent including those formed after the Effe |
|
| March 31, 2021 |
MEDICAL OUTCOMES RESEARCH ANALYTICS, LLC Exhibit 10.4 MEDICAL OUTCOMES RESEARCH ANALYTICS, LLC Confidential March 25, 2020 Adam Dublin Re: Conditional Offer of Employment Hi Adam, This offer letter provides the key details of our conditional offer of employment to you by Medical Outcomes Research Analytics, LLC (?MOR?) with respect to the business of MOR and its subsidiaries (together with MOR, the ?Company Group?). Position You will ser |
|
| March 31, 2021 |
Exhibit 10.6 EXECUTION COPY EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of March 1, 2021 (the ?Effective Date?), by and between Forian Inc., a Delaware corporation (the ?Company?), and Edward Spaniel, Jr. (?Executive?). The Company and Executive desire to enter into this Agreement to establish and govern the terms and conditions of Executive?s employment by the Com |
|
| March 5, 2021 |
As filed with the Securities and Exchange Commission on March 5, 2021 Registration No. |
|
| March 3, 2021 |
Exhibit 99.1 Forian launched through combination of Helix Technologies and Medical Outcomes Research Analytics Innovative technology platform delivers measurable operating and business improvements to healthcare and cannabis markets Newtown, PA, March 2, 2021 ? Forian Inc. announced that it has completed the combination of Helix Technologies, Inc. (OTCQB:HLIX) and Medical Outcomes Research Analyti |
|
| March 3, 2021 |
EQUITY INTEREST CONTRIBUTION AGREEMENT Exhibit 2.4 EXECUTION VERSION EQUITY INTEREST CONTRIBUTION AGREEMENT This EQUITY INTEREST CONTRIBUTION AGREEMENT (this ?Agreement?) is made and entered into as of March 2, 2021 by and among Forian Inc., a Delaware corporation (?Parent?), Medical Outcomes Research Analytics, LLC, a Delaware limited liability company (?MOR?), and the undersigned equityholders of MOR (collectively, the ?Equityholders |
|
| March 3, 2021 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of March 2, 2021 between Forian Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided with adequate protection |
|
| March 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2021 FORIAN INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40146 85-3467693 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 FORIAN INC. (Exact name of registrant as specified in its charter) Delaware 85-3467693 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 41 Univ |
|
| February 25, 2021 |
Filed by Forian Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Forian Inc. SEC File No.: 333-250938 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date |
|
| February 16, 2021 |
HELIX TECHNOLOGIES, INC. 5300 DTC PARKWAY, Suite 300 Greenwood Village, CO 80111 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-250938 ? HELIX TECHNOLOGIES, INC. 5300 DTC PARKWAY, Suite 300 Greenwood Village, CO 80111 February 11, 2021 Dear Fellow Stockholder: On October 16, 2020, Helix Technologies, Inc., or ?Helix,? Forian Inc., or ?Forian,? and Medical Outcomes Research Analytics, LLC, or ?MOR? entered into an Agreement and Plan of Merger, as amende |
|
| February 9, 2021 |
Exhibit 2.3 AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of February 9, 2021, among Helix Technologies, Inc., a Delaware corporation (the “Company”), Forian Inc., a Delaware corporation (“Parent”), DNA Merger Sub Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Medical Outco |
|
| February 9, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 9, 2021 Registration No. |
|
| February 9, 2021 |
FORIAN INC. 41 University Drive, Suite 400 Newtown, PA 18940 February 9, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Office of Technology Re: Forian Inc. Registration Statement on Form S-4 Filed February 9, 2021 File No. 333-250938 Dear Ladies and Gentlemen: Pursuant to Rule 461 under the Securities |
|
| February 1, 2021 |
February 1, 2021 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| February 1, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 1, 2021 Registration No. |
|
| February 1, 2021 |
Exhibit 10.2 Execution Copy CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. License Agreement THIS LICENSE AGREEMENT (this “Agreement”) is entered into as of June 30, 2019 (“Effective Date”) by and between DR/Decisio |
|
| January 19, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 19, 2021 Registration No. |
|
| January 19, 2021 |
NEW YORK LONDON SINGAPORE PHILADELPHIA CHICAGO WASHINGTON, DC SAN FRANCISCO SILICON VALLEY SAN DIEGO LOS ANGELES TAIWAN BOSTON HOUSTON AUSTIN HANOI HO CHI MINH CITY FIRM and AFFILIATE OFFICES www. |
|
| January 7, 2021 |
Filed by Forian Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Forian Inc. SEC File No.: 333-250938 On January 7, 2021, Medical Outcomes Research Analytics LLC sent the following communication to its investors: Hi, I hope you had a happy holidays and healthy new year. This is to let you |
|
| December 31, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 31, 2020 Registration No. |
|
| December 31, 2020 |
FORIAN Inc. 2020 EQUITY INCENTIVE PLAN Exhibit 4.1 FORIAN Inc. 2020 EQUITY INCENTIVE PLAN The purpose of the Forian Inc. 2020 Equity Incentive Plan is to provide (i) designated employees of Forian Inc. (the “Company”) and its parents and subsidiaries, (ii) certain consultants and advisors who perform services for the Company or its parents or subsidiaries and (iii) non-employee members of the Board of Directors of the Company (the “Boa |
|
| December 31, 2020 |
Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of October 16, 2020 by and among Forian Inc., a Delaware corporation (“Parent”), on the one hand, and the undersigned securityholder (a “Securityholder”) of Helix Technologies, Inc., a Delaware corporation (the “Company”), on the other hand. RECITALS WHEREAS, concurrently with |
|
| December 31, 2020 |
Consent to be Named as a Director Nominee EX-99.9 8 nt10016579x4ex99-9.htm EXHIBIT 99.9 Exhibit 99.9 Consent to be Named as a Director Nominee In connection with the filing by Forian, Inc. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to be |
|
| December 31, 2020 |
Exhibit 10.2 Execution Copy CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. License Agreement THIS LICENSE AGREEMENT (this “Agreement”) is entered into as of June 30, 2019 (“Effective Date”) by and between [***] (“Co |
|
| December 31, 2020 |
AMENDMENT TO AGREEMENT AND PLAN OF MERGER Exhibit 2.2 AMENDMENT TO AGREEMENT AND PLAN OF MERGER This AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of December 30, 2020, among Helix Technologies, Inc., a Delaware corporation (the “Company”), Forian Inc., a Delaware corporation (“Parent”), DNA Merger Sub Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Medical Outcomes Researc |
|
| December 31, 2020 |
NEW YORK LONDON SINGAPORE PHILADELPHIA CHICAGO WASHINGTON, DC SAN FRANCISCO SILICON VALLEY SAN DIEGO LOS ANGELES TAIWAN BOSTON HOUSTON AUSTIN HANOI HO CHI MINH CITY FIRM and AFFILIATE OFFICES www. |
|
| December 31, 2020 |
Consent to be Named as a Director Nominee EX-99.10 9 nt10016579x4ex99-10.htm EXHIBIT 99.10 Exhibit 99.10 Consent to be Named as a Director Nominee In connection with the filing by Forian, Inc. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, t |
|
| November 25, 2020 |
Filed by Forian Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Forian Inc. SEC File No.: 333-250938 On November 25, 2020, Medical Outcomes Research Analytics LLC sent the following communication to its investors: Dear MOR Investor, This is an update regarding the status of MOR’s combinat |
|
| November 24, 2020 |
Consent to be Named as a Director Nominee Exhibit 99.6 Consent to be Named as a Director Nominee In connection with the filing by Forian, Inc. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directo |
|
| November 24, 2020 |
Consent to be Named as a Director Nominee Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by Forian, Inc. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directo |
|
| November 24, 2020 |
Exhibit 99.8 |
|
| November 24, 2020 |
BY-LAWS OF FORIAN INC. (a Delaware corporation) Effective as of October 15, 2020 TABLE OF CONTENTS Exhibit 3.2 BY-LAWS OF FORIAN INC. (a Delaware corporation) Effective as of October 15, 2020 TABLE OF CONTENTS Page ARTICLE 1 OFFICES Section 1.1 Registered Office. 1 Section 1.2 Other Offices. 1 ARTICLE 2 CORPORATE SEAL Section 2.1 Corporate Seal 1 ARTICLE 3 STOCKHOLDERS’ MEETINGS Section 3.1 Place of Meetings 1 Section 3.2 Annual Meetings 1 Section 3.3 Special Meetings 5 Section 3.4 Notice of Me |
|
| November 24, 2020 |
CERTIFICATE OF INCORPORATION FORIAN INC. ARTICLE 1 Exhibit 3.1 CERTIFICATE OF INCORPORATION OF FORIAN INC. ARTICLE 1 The name of the Corporation is Forian Inc. ARTICLE 2 The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808. The name of the Corporation’s registered agent at such address is Corporation Service Company. ARTICLE 3 The purpose of |
|
| November 24, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 24, 2020 Registration No. |
|
| November 24, 2020 |
Consent to be Named as a Director Nominee Exhibit 99.7 Consent to be Named as a Director Nominee In connection with the filing by Forian, Inc. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directo |
|
| November 24, 2020 |
Consent to be Named as a Director Nominee Exhibit 99.5 Consent to be Named as a Director Nominee In connection with the filing by Forian, Inc. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directo |
|
| November 24, 2020 |
Consent to be Named as a Director Nominee Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by Forian, Inc. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directo |
|
| November 5, 2020 |
HLIX / Helix TCS, Inc. / Forian Inc. - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Helix Technologies, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 42333M101 (CUSIP Number) Daniel Barton Chief Executive Officer Forian Inc. 41 University Drive, Suite 405 Newtown, PA 18940 (267) 757-8707 (Name, Address a |
|
| October 21, 2020 |
Filed by Forian Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Helix Technologies, Inc. SEC File No.: 000-55722 Helix Technologies, Inc. and Medical Outcomes Research Analytics, LLC to Combine October 17, 2020 12:30 PM DENVER and NEWTOWN, Pa., Oct. 17, 2020 /PRNe |
|
| October 21, 2020 |
HLIX / Helix TCS, Inc. / Forian Inc. - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Helix Technologies, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 42333M101 (CUSIP Number) Daniel Barton Chief Executive Officer Forian Inc. 41 University Drive, Suite 405 Newtown, PA 18940 (267) 757-8707 (Name, Address an |
